Publications

Detection of plasmid-encoded CFR in clinical isolates of Enterococcus faecalis from Panamá City: report from the SENTRY Antimicrobial Surveillance Programme, Lead author: Mendes RE, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Susceptibility rates in Latin American nations: report from the Emerging Markets Resistance Surveillance Programme, Lead author: Jones RN, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Resistance surveillance programme report for European nations (2011), Lead author: Jones RN, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Longitudinal assessment of tigecycline activity tested against Gram-positive and Gram-negative organisms from European medical centres: results from the SENTRY Programme (2004-2012), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Antimicrobial susceptibility of Gram-negative bacteria causing urinary tract infections in European and United States hospitals (2009-2011), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Screening for fluoroquinolone-resistance in staphylococcus aureus and Streptococcus spp using norfloxacin and EUCAST disc diffusion criteria, Lead author: Ahman, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Improved screen for beta-lactam-resistance in Streptococcus pneumoniae with the oxacillin 1-ug disk using the EUCAST disc diffusion method, Lead author: Matuschek, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Biapenem and biapenem/RPX7009 MIC quality control ranges using CLSI multi-laboratory M23-A3 study design, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of aztreonam combined with the beta-lactamase inhibitor avibactam tested against metallo beta-lactamase-producing organisms, Lead author: Castanheira M, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Antimicrobial activity of ceftaroline and comparator agents tested against organisms causing skin and soft tissue infections in European medical centres (2011), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Antimicrobial activity of ceftaroline combined with avibactam tested against contemporary (2012) bacteria collected from USA patients with acute bacterial skin and skin structure infections, Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens (2008-2011), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftaroline against the leading community-acquired respiratory tract infection pathogens in Europe and the Mediterranean region, 2011, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftobiprole tested against pathogens associated with hospital-acquired bacterial pneumonia in Europe, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftobiprole tested against pathogens associated with community-acquired bacterial pneumonia in Europe, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftobiprole tested against Gram-negative clinical isolates from European medical centres, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftobiprole tested against clinical isolates of staphylococci and streptococci from European surveillance (2008-2010), Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus including strains with reduced susceptibility to daptomycin, linezolid, and vancomycin, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Pseudomonas aeruginosa isolates from 14 European countries and Israel, Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Oritavancin activity tested against Staphylococcus aureus and beta-haemolytic streptococci causing skin and soft tissue infections in the European Union and other countries (2010-2012), Lead author: Mendes RE, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Assessment of oritavancin activity tested against contemporary clinical isolates responsible for documented bacteremia in the European Union and other countries (2010-2012), Lead author: Mendes RE, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Dalbavancin activity in the USA: reported from the SENTRY Programme (2012), Lead author: Jones RN, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model, Lead author: Bhavnani, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Recent Resistance Surveillance Results from 12 Medical Centres Across China (2011), Lead author: Mendes RE, presented at 9th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 12 – 15, 2013, Kuala Lumpur, Malaysia

Molecular Characterization of Vancomycin-resistant Enterococcus Clinical Isolates Recovered from Hospitalized Patients in China, Lead author: Mendes RE, presented at 9th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 12 – 15, 2013, Kuala Lumpur, Malaysia

Emerging Markets Resistance Surveillance Programme Report for 12 Asia-Pacific Nations (2011), Lead author: Mendes RE, presented at 9th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 12 – 15, 2013, Kuala Lumpur, Malaysia

Telavancin In Vitro Activity Against a Contemporary(2011–2012) Collection of Gram-positive Pathogens, Lead author: Mendes RE, presented at 9th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 12 – 15, 2013, Kuala Lumpur, Malaysia

10 x ’20 Progress–Development of new drugs active against Gram-negative bacilli: An update from the Infectious Diseases Society of America. by Boucher HW, Talbot GH, Benjamin DK, Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA and Gilbert D for the Infectious Diseases Society of America published in Clin. Infect. Dis. 2013; 56 (12): 1685-1694

Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. by VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN and Ambrose PG. published in Antimicrob. Agents Chemother. 2013; 57 (6): 2809-2814

An evaluation of vancomycin susceptibility testing for methicillin-resistant S. aureus: A comparison of Etest and three automated testing methods. by Rybak MJ, Vidaillac C, Sader H, Rhomberg P, Salimnia H, Briski L, Wanger A and Jones R published in J. Clin. Microbiol. 2013; 51 (7): 2077-2081

Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and non-fermentative Gram-negative bacilli. by Mendes RE, Alley MR, Sader HS, Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 2013; 57 (6): 2849-2857

Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin or vancomycin from USA hospitals (2008–2011). by Sader HS, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2013; 57 (7): 3178-3181

Linezolid surveillance results for the United States: LEADER Surveillance Program 2011. by Flamm RK, Mendes RE, Ross JE, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2013; 57 (2): 1077-1081

Contemporary potencies of minocycline and tetracycline HCL tested against gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria. by Jones RN, Wilson ML, Weinstein MP, Stilwell MG and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 402-405

Contemporary tetracycline susceptibility testing: Doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing gram-positive pathogens. by Jones RN, Stilwell MG, Wilson ML and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2013; 76 (1): 69-72

More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA. by Jones RN, Sader HS, Flamm RK and Watters AA published in Diagn. Microbiol. Infect. Dis. 2013; 76 (1): 110-112

Activities of carbapenem and comparator agents against contemporary U.S. Pseudomonas aeruginosa isolates from the CAPITAL surveillance program. by Morrow BJ, Pillar CM, Deane J, Sahm D, Lynch AS, Flamm RK, Peterson J and Davies TA. published in Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 412-416

The genetic environment of the cfr gene and the presence of other mechanisms account for the very high linezolid resistance of the Staphylococcus epidermidisisolate 426-3147L. by LaMarre J, Mendes RE, Szal T, Schwarz S, Jones RN and Mankin AS published in Antimicrob. Agents Chemother. 2013; 57 (3): 1173-1179

Background and rationale for revised Clinical Laboratory Standards Institute (CLSI) interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam. by Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ and Jones RN published in Clin. Infect. Dis. 2013; 56 (9): 1301-1309

Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: Report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). by Jones RN, Sader HS, Mendes RE and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2013; 75 (1): 107-109

Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. by Vaara M, Sader HS, Rhomberg PR, Jones RN and Vaara T published in J. Antimicrob. Chemother. 2013; 68 (3): 636-639

Candida guilliermondii and other species of Candida misidentified as Candida famata: Assessment by Vitek2, ITS sequence analysis and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry in two global surveillance programs. by Castanheira M, Woosley LN, Diekema DJ, Jones RN and Pfaller MA published in J. Clin. Microbiol. 2013; 51 (1): 117-124

Update on the prevalence and genetic characterization of NDM-1-producing Enterobacteriaceae in Indian hospitals during 2010. by Castanheira M, Deshpande LM, Farrell SE, Shetye S, Shah N and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 75 (2): 210-213

Activity of MK-3118, a new oral glucan synthase inhibitor tested against Candida spp. by two international methods (CLSI and EUCAST). by Pfaller MA, Messer SA, Motyl MR, Jones RN and Castanheira M published in J. Antimicrob. Chemother. 2013; 68 (4): 858-863

In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. by Pfaller MA, Messer SA, Motyl MR, Jones RN and Castanheira M published in Antimicrob. Agents Chemother. 2013; 57 (2): 1065-1068

Determination of disk diffusion and MIC quality control guidelines for GSK2251052: A novel boron antibacterial. by Ross JE, Scangarella-Oman NE and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 437-439

Update of dalbavancin spectrum and potency in the USA; Report from the SENTRY Antimicrobial Surveillance Program (2011). by Jones RN, Sader HS and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2013; 75 (3): 304-307

Surveillance of dalbavancin potency and spectrum in the United States (2012). by Jones RN, Flamm RK and Sader HS published in Diagn. Microbiol. Infect. Dis. 2013; 76 (1): 122-123

Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: Selecting potent surrogate ß-lactam markers to predict ceftaroline activity against clinically-indicated species. by Jones RN, Flamm RK, Sader HS and Stilwell MG published in Diagn. Microbiol. Infect. Dis. 2013; 75 (1): 89-93

Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). by Farrell DJ, Flamm RK, Jones RN and Sader HS published in Diagn. Microbiol. Infect. Dis. 2013; 75 (1): 86-88